Endoskopia Sp. z o.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
At Endoskopia Sp. z o.o. in Sopot, most clinical research focuses on digestive system diseases, especially inflammatory bowel disease and related gastrointestinal conditions. The studies are designed to test new treatments, compare them with placebo or standard care, and better understand how to improve symptom control and long-term outcomes.
- Ulcerative colitis, including moderate to severe and long-term management studies
- Crohn’s disease, including active, refractory, and fibrostenotic forms
- Gastroparesis and other disorders affecting stomach emptying and digestive function
This research portfolio reflects a strong emphasis on evaluating both the effectiveness and safety of emerging therapies for chronic gastroenterology conditions.
Immune System Diseases
The site also contributes to trials in immune system diseases, with a particular focus on immune-mediated inflammation affecting the gut. These studies aim to assess whether targeted therapies can reduce disease activity, maintain remission, and improve quality of life for people living with chronic inflammatory conditions.
- Immune-mediated inflammatory bowel disease and related immune disorders
- Ulcerative colitis as a major immune-driven disease area
- Crohn’s disease, including studies of treatment response and maintenance of benefit
The research at this hospital/clinic includes both short-term treatment evaluation and longer-term follow-up, helping determine how immune-targeted approaches perform over time.
Immune System Phenomena
Clinical trials here also explore immune system phenomena, especially the biological processes behind inflammation and healing in gastrointestinal disease. The goal is to better characterize how novel therapies affect immune activity, tissue inflammation, and endoscopic signs of disease improvement.
- Targeted immunologic treatment responses in inflammatory bowel disease
- Endoscopic response and other markers of intestinal healing
- Long-term safety and tolerability of new immune-based therapies
With 42 clinical trials and multiple investigators involved, the site supports research that links immune biology with practical treatment advances for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 51 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Endoskopia Sp. z o.o.
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 6 | Unknown | 2023-03-17 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.